Diabetes and COVID-19: Global and regional perspectives.
Identifieur interne : 000077 ( Main/Corpus ); précédent : 000076; suivant : 000078Diabetes and COVID-19: Global and regional perspectives.
Auteurs : In-Kyung Jeong ; Kun Ho Yoon ; Moon Kyu LeeSource :
- Diabetes research and clinical practice [ 1872-8227 ] ; 2020.
Abstract
The coronavirus disease-2019 (COVID-19) has been designated as a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) since December 2019, when an outbreak of pneumonia cases emerged in Wuhan, China. The COVID-19 pandemic has led to a global health crisis, devastating the social, economic and political aspects of life. Many clinicians, health professionals, scientists, organizations, and governments have actively defeated COVID-19 and shared their experiences of the SARS-CoV2. Diabetes is one of the major risk factors for fatal outcomes from COVID-19. Patients with diabetes are vulnerable to infection because of hyperglycemia; impaired immune function; vascular complications; and comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. In addition, angiotensin-converting enzyme 2 (ACE2) is a receptor for SARS-CoV-2 in the human body. Hence, the use of angiotensin-directed medications in patients with diabetes requires attention. The severity and mortality from COVID-19 was significantly higher in patients with diabetes than in those without. Thus, the patients with diabetes should take precautions during the COVID-19 pandemic. Therefore, we review the current knowledge of COVID-19 including the global and regional epidemiology, virology, impact of diabetes on COVID-19, treatment of COVID-19, and standard of care in the management of diabetes during this critical period.
DOI: 10.1016/j.diabres.2020.108303
PubMed: 32623038
PubMed Central: PMC7332438
Links to Exploration step
pubmed:32623038Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diabetes and COVID-19: Global and regional perspectives.</title><author><name sortKey="Jeong, In Kyung" sort="Jeong, In Kyung" uniqKey="Jeong I" first="In-Kyung" last="Jeong">In-Kyung Jeong</name><affiliation><nlm:affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea. Electronic address: jik1016@naver.com.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Kun Ho" sort="Yoon, Kun Ho" uniqKey="Yoon K" first="Kun Ho" last="Yoon">Kun Ho Yoon</name><affiliation><nlm:affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: yoonk@catholic.ac.kr.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Moon Kyu" sort="Lee, Moon Kyu" uniqKey="Lee M" first="Moon Kyu" last="Lee">Moon Kyu Lee</name><affiliation><nlm:affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunghyang University College of Medicine, Gumi, Republic of Korea. Electronic address: leemk4132@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32623038</idno><idno type="pmid">32623038</idno><idno type="doi">10.1016/j.diabres.2020.108303</idno><idno type="pmc">PMC7332438</idno><idno type="wicri:Area/Main/Corpus">000077</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000077</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Diabetes and COVID-19: Global and regional perspectives.</title><author><name sortKey="Jeong, In Kyung" sort="Jeong, In Kyung" uniqKey="Jeong I" first="In-Kyung" last="Jeong">In-Kyung Jeong</name><affiliation><nlm:affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea. Electronic address: jik1016@naver.com.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Kun Ho" sort="Yoon, Kun Ho" uniqKey="Yoon K" first="Kun Ho" last="Yoon">Kun Ho Yoon</name><affiliation><nlm:affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: yoonk@catholic.ac.kr.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Moon Kyu" sort="Lee, Moon Kyu" uniqKey="Lee M" first="Moon Kyu" last="Lee">Moon Kyu Lee</name><affiliation><nlm:affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunghyang University College of Medicine, Gumi, Republic of Korea. Electronic address: leemk4132@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Diabetes research and clinical practice</title><idno type="eISSN">1872-8227</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus disease-2019 (COVID-19) has been designated as a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) since December 2019, when an outbreak of pneumonia cases emerged in Wuhan, China. The COVID-19 pandemic has led to a global health crisis, devastating the social, economic and political aspects of life. Many clinicians, health professionals, scientists, organizations, and governments have actively defeated COVID-19 and shared their experiences of the SARS-CoV2. Diabetes is one of the major risk factors for fatal outcomes from COVID-19. Patients with diabetes are vulnerable to infection because of hyperglycemia; impaired immune function; vascular complications; and comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. In addition, angiotensin-converting enzyme 2 (ACE2) is a receptor for SARS-CoV-2 in the human body. Hence, the use of angiotensin-directed medications in patients with diabetes requires attention. The severity and mortality from COVID-19 was significantly higher in patients with diabetes than in those without. Thus, the patients with diabetes should take precautions during the COVID-19 pandemic. Therefore, we review the current knowledge of COVID-19 including the global and regional epidemiology, virology, impact of diabetes on COVID-19, treatment of COVID-19, and standard of care in the management of diabetes during this critical period.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32623038</PMID><DateRevised><Year>2020</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8227</ISSN><JournalIssue CitedMedium="Internet"><Volume>166</Volume><PubDate><Year>2020</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Diabetes research and clinical practice</Title><ISOAbbreviation>Diabetes Res. Clin. Pract.</ISOAbbreviation></Journal><ArticleTitle>Diabetes and COVID-19: Global and regional perspectives.</ArticleTitle><Pagination><MedlinePgn>108303</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-8227(20)30555-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.diabres.2020.108303</ELocationID><Abstract><AbstractText>The coronavirus disease-2019 (COVID-19) has been designated as a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) since December 2019, when an outbreak of pneumonia cases emerged in Wuhan, China. The COVID-19 pandemic has led to a global health crisis, devastating the social, economic and political aspects of life. Many clinicians, health professionals, scientists, organizations, and governments have actively defeated COVID-19 and shared their experiences of the SARS-CoV2. Diabetes is one of the major risk factors for fatal outcomes from COVID-19. Patients with diabetes are vulnerable to infection because of hyperglycemia; impaired immune function; vascular complications; and comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. In addition, angiotensin-converting enzyme 2 (ACE2) is a receptor for SARS-CoV-2 in the human body. Hence, the use of angiotensin-directed medications in patients with diabetes requires attention. The severity and mortality from COVID-19 was significantly higher in patients with diabetes than in those without. Thus, the patients with diabetes should take precautions during the COVID-19 pandemic. Therefore, we review the current knowledge of COVID-19 including the global and regional epidemiology, virology, impact of diabetes on COVID-19, treatment of COVID-19, and standard of care in the management of diabetes during this critical period.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>In-Kyung</ForeName><Initials>IK</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea. Electronic address: jik1016@naver.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Kun Ho</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address: yoonk@catholic.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Moon Kyu</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunghyang University College of Medicine, Gumi, Republic of Korea. Electronic address: leemk4132@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Diabetes Res Clin Pract</MedlineTA><NlmUniqueID>8508335</NlmUniqueID><ISSNLinking>0168-8227</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin-converting enzyme 2</Keyword><Keyword MajorTopicYN="N">Coronavirus disease-2019 (COVID-19)</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Severe acute respiratory syndrome coronavirus-2</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32623038</ArticleId><ArticleId IdType="pii">S0168-8227(20)30555-6</ArticleId><ArticleId IdType="doi">10.1016/j.diabres.2020.108303</ArticleId><ArticleId IdType="pmc">PMC7332438</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000077 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000077 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32623038
|texte= Diabetes and COVID-19: Global and regional perspectives.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32623038" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |